As always, we were pleased to have the opportunity to catch-up with valued editorial board member Heinz Reichmann (Technische Universität Dresden, Dresden, Germany), who spoke to us on the topic of the lecture he gave during the on-demand sessions entitled: The Gut Microbiome in the Pathogenesis of Parkinson’s Disease.
1. Could you tell us about the association between constipation and Parkinson’s disease (PD)? (0:06)
2. Could you give us an overview of the evidence supporting the hypothesis that α-synuclein pathology originates in the gut and spreads to the enteric nervous system? (0:33)
3. What have these findings taught us about the cause of PD? (1:16)
4. Could you give us an overview of the key scientific data supporting a role of the gut microbiome in the development of PD? (2:15)
5. How can these findings potentially be used to improve treatment? (3:20)
Disclosures: Prof. Reichmann has no financial or non-financial relationships or activities to declare in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!